HEMGENIX OPTIONS

Amount of qualified patients: CDEC talked about the uncertainty in the volume of individuals with reasonably intense to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some people that are categorized as having mild or moderate disorder may have a significant bleeding phenoty